P2RY12 and Stroke: The available data from clinical studies and registries seem to favor dual therapy with a DOAC plus a P2Y12 inhibitor to prevent stroke, stent thrombosis and coronary ischemic events in AF patients who undergo percutaneous coronary intervention for ACS [28].